| Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms (NCT05455294) | Jacqueline Garcia, MD | 2022-07-18 |
| A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies (NCT05362773) | MacroGenics | 2022-07-13 |
| Hetrombopag for Lower-risk MDS With Thrombocytopenia: a Prospective，Open-label, Single-arm Study. (NCT05392647) | Tongji Hospital | 2022-07-01 |
| Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS (NCT04893915) | Washington University School of Medicine | 2022-06-30 |
| Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation (NCT05005299) | Melbourne Health | 2022-06-08 |
| Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia (NCT05320198) | Disc Medicine, Inc | 2022-06-06 |
| A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies (NCT05428969) | Faron Pharmaceuticals Ltd | 2022-06-02 |
| Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS (NCT05342584) | Montefiore Medical Center | 2022-05-25 |
| Feasibility Study to Assess an Adapted Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Transplantation (NCT05298930) | Centre Leon Berard | 2022-05-25 |
| Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA (NCT05181735) | Groupe Francophone des Myelodysplasies | 2022-05-18 |
| Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant (NCT04742634) | Washington University School of Medicine | 2022-05-12 |
| Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients (NCT05237713) | University of Leipzig | 2022-04-26 |
| COaching and Prehabilitation: Faisability Study in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome (NCT03595787) | Institut Paoli-Calmettes | 2022-04-04 |
| Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML (NCT05184842) | Montefiore Medical Center | 2022-03-23 |
| PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies (NCT05107856) | Prelude Therapeutics | 2022-03-22 |
| Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML (NCT05275439) | Shattuck Labs, Inc. | 2022-03-17 |
| PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation (NCT05120570) | Masonic Cancer Center, University of Minnesota | 2022-03-17 |
| Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression for Ruling Out Myelodysplastic Syndromes: Protocol for a Diagnostic Accuracy Study (NCT05175469) | University Hospital, Grenoble | 2022-03-01 |
| Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML (NCT05584761) | The First Affiliated Hospital with Nanjing Medical University | 2022-03-01 |
| A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) (NCT04988555) | Sumitomo Pharma America, Inc. | 2022-02-28 |
| A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) (NCT05218902) | Bristol-Myers Squibb | 2022-02-25 |
| Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms (NCT04902833) | Massachusetts General Hospital | 2022-02-01 |
| MBG453 in Lower Risk MDS (NCT04823624) | Massachusetts General Hospital | 2022-01-27 |
| A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes (NCT05168202) | Bristol-Myers Squibb | 2022-01-19 |
| A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies (NCT04937166) | Kahr Medical | 2022-01-13 |
| A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome (NCT05140811) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2022-01-05 |
| Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948 (NCT05178342) | University of Leipzig | 2022-01-01 |
| Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS (NCT04849910) | Vor Biopharma | 2021-12-16 |
| Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment (NCT04953897) | Taiho Oncology, Inc. | 2021-12-15 |
| First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (NCT05086315) | Sanofi | 2021-12-08 |
| Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease (NCT04328714) | Edwin Horwitz | 2021-12-02 |
| Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes (NCT04951778) | Celgene | 2021-12-02 |
| Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients (NCT04539236) | Mikkael Sekeres, MD | 2021-11-09 |
| Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome. (NCT05181592) | GWT-TUD GmbH | 2021-10-27 |
| Population Pharmacokinetic Study Based on Quantitative Pharmacology in Patients With Lenalidomide (NCT06069024) | Qianfoshan Hospital | 2021-10-15 |
| HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (NCT04904588) | Center for International Blood and Marrow Transplant Research | 2021-09-30 |
| Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. (NCT04866056) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2021-09-30 |
| APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS) (NCT04638309) | Aprea Therapeutics | 2021-09-20 |
| Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS (NCT04986657) | Washington University School of Medicine | 2021-09-17 |
| Inqovi Maintenance Therapy in Myeloid Neoplasms (NCT04980404) | Massachusetts General Hospital | 2021-09-17 |
| Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT (NCT05066958) | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 2021-09-16 |
| Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT (NCT04764513) | Chinese PLA General Hospital | 2021-09-12 |
| Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft (NCT05088356) | Stanford University | 2021-09-07 |
| To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma (NCT04582539) | Incyte Corporation | 2021-08-19 |
| A Study of E7820 in People With Bone Marrow (Myeloid) Cancers (NCT05024994) | Memorial Sloan Kettering Cancer Center | 2021-08-13 |
| Study to Evaluate Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs) (NCT04973280) | Celgene | 2021-07-26 |
| Removing Transfusion Dependence as a Barrier to Hospice Enrollment (NCT05063591) | Adam Olszewski | 2021-07-09 |
| Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome (NCT04999943) | Affiliated Hospital to Academy of Military Medical Sciences | 2021-07-01 |
| Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS (NCT04810611) | Novartis Pharmaceuticals | 2021-06-18 |
| Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens (NCT04968834) | Dana-Farber Cancer Institute | 2021-06-11 |
| Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence (NCT04797000) | Novartis Pharmaceuticals | 2021-05-25 |
| A Study of BGB-11417 in Participants With Myeloid Malignancies (NCT04771130) | BeOne Medicines | 2021-05-24 |
| Physical Activity in Transfusion Dependent Patients With Myelodysplastic Syndrome (NCT04969367) | Thomas Jefferson University | 2021-05-10 |
| A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT) (NCT04264806) | Janssen Research & Development, LLC | 2021-05-06 |
| BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS (NCT04827719) | Groupe Francophone des Myelodysplasies | 2021-05-01 |
| CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome (NCT03929211) | Wake Forest University Health Sciences | 2021-05-01 |
| A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML (NCT04730258) | Treadwell Therapeutics, Inc | 2021-04-16 |
| Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome (NCT05263271) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2021-04-01 |
| Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA (NCT04798339) | H. Lee Moffitt Cancer Center and Research Institute | 2021-03-30 |
| A Telehealth Advance Care Planning Intervention for Older Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome (NCT04745676) | University of Rochester | 2021-03-25 |
| Impact of 2 Transfusion Strategies on Quality of Life of Multitransfused Patients With Low-risk Myelodysplastic Syndrome (NCT03643042) | Lille Catholic University | 2021-03-24 |
| GENOMED4ALL: Improving MDS Classification and Prognosis by AI (NCT04889729) | Istituto Clinico Humanitas | 2021-03-15 |
| IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation (NCT04628338) | Sawa Ito, MD | 2021-03-08 |
| Thrombosomes® in Bleeding Thrombocytopenic Patients Study (NCT04631211) | Cellphire Therapeutics, Inc. | 2021-03-05 |
| Interplay Between Immune and Metabolic Programs in Myelodysplastic Syndromes (NCT04803721) | University Hospital, Toulouse | 2021-02-23 |
| Methods of T Cell Depletion Trial (MoTD) (NCT04888741) | University of Birmingham | 2021-02-22 |
| Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT (NCT04629430) | University of Virginia | 2021-02-19 |
| Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS Patients (NCT04587856) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2021-02-12 |
| Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome (NCT04797780) | Syros Pharmaceuticals | 2021-02-08 |
| Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe) (NCT04942730) | St. Petersburg State Pavlov Medical University | 2021-01-21 |
| Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies (NCT04943757) | St. Petersburg State Pavlov Medical University | 2021-01-21 |
| CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML (NCT04620681) | H. Lee Moffitt Cancer Center and Research Institute | 2021-01-14 |
| IS-free Treg HaploHCT (NCT04678401) | Dana-Farber Cancer Institute | 2021-01-12 |
| NTX-301 in MDS/AML (NCT04167917) | University of Alabama at Birmingham | 2021-01-06 |
| Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) (NCT04095858) | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2021-01-05 |
| Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat (NCT04712942) | University of Leipzig | 2021-01-01 |
| MyPal ePRO-based Early Palliative Care System in Adult Patients With Hematologic Malignancies (NCT04370457) | Centre for Research and Technology Hellas | 2021-01-01 |
| Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms (NCT04460950) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2020-12-16 |
| A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS (NCT04358393) | Ascentage Pharma Group Inc. | 2020-12-04 |
| A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (NCT04609826) | Janssen Research & Development, LLC | 2020-11-26 |
| 5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies (NCT04187703) | Benjamin Tomlinson | 2020-11-16 |
| Study to Evaluate the Safety and Tolerability of EP0042 (NCT04581512) | Ellipses Pharma | 2020-11-02 |
| A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS (NCT04477291) | Aptose Biosciences Inc. | 2020-10-06 |
| Haploinsufficiency of the RBM22 and SLU7 Genes in Del(5q) Myelodysplastic Syndromes (NCT04701229) | University Hospital, Brest | 2020-09-30 |
| Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS (NCT04485065) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-09-30 |
| A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies (NCT04543305) | Prelude Therapeutics | 2020-09-28 |
| Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) (NCT04313881) | Gilead Sciences | 2020-09-09 |
| Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker (NCT04003220) | University Hospital, Bordeaux | 2020-09-07 |
| Could Ki-67 be Used as a Diagnostic or Prognostic Marker in Hemato-oncological Diagnostics? (NCT04517175) | Maastricht University | 2020-09-01 |
| IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT (NCT04522895) | Heinrich-Heine University, Duesseldorf | 2020-08-27 |
| Analysis of Risk in MDS Over Time - Comparison of Treated vs Untreated Patients (NCT04676945) | Michael Pfeilstöcker | 2020-08-21 |
| Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS (NCT04482894) | University of Virginia | 2020-08-19 |
| A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) (NCT04419649) | Takeda | 2020-08-19 |
| Haplo Peripheral Blood Sct In GVHD Prevention (NCT04473911) | Zachariah Michael DeFilipp | 2020-08-14 |
| Development and Prospective Validation of a Standardized Flow Cytometric Assay of Peripheral Blood Neutrophil Myeloperoxidase Expression for Ruling Out Myelodysplastic Syndromes. (NCT04399018) | University Hospital, Grenoble | 2020-07-27 |
| HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation (NCT04464889) | Medigene AG | 2020-07-02 |
| Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant (NCT03964506) | Omar Aljitawi | 2020-07-01 |
| Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome (NCT04245397) | Syntrix Biosystems, Inc. | 2020-06-30 |
| A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML (NCT05933070) | Inmune Bio, Inc. | 2020-06-15 |
| Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) (NCT04266301) | Novartis Pharmaceuticals | 2020-06-08 |